type here...

Opioid Crisis

Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be

Jessie Wrobel
New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones. Economists love health care because it...

The Rise of the Opioids: How Purdue Invented New Markets for OxyContin

David Egilman, Gregory Collins, Julie Falender, Naomi Shembo, Ciara Keegan, Sunil Tohan
Purdue's strategy was to market its opioids directly to patients via brochures, videos, advertisements, and the internet. It also provided information to doctors and...

Editors’ Briefing: On Our Radar This Week (Feb. 24–March 3)

ProMarket writers
This week in political economy.       Italy’s elections are on Sunday, and with the polls being inconclusive and the reemergence of former PM Silvio Berlusconi...

Editors’ Briefing: On Our Radar This Week (Feb. 17–Feb. 24)

ProMarket writers
This week in political economy.     Is the US economy being strangled by a lack of competition? In the Harvard Business Review, David Wessel provides...

LATEST NEWS

The publication of the Stigler Center at The University of Chicago Booth School of Business

ProMarket is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not necessarily those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Policy.